TMO
Thermo Fisher Scientific Inc
$448.18
-$0.10(-0.02%)
50
Overall
75
Value
33
Tech
44
Quality
Market Cap
$166.42B
Volume
1.94M
52W Range
$385.46 - $643.99
Target Price
$615.18
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $18.3B | $20.9B | $24.4B | $25.5B | $32.2B | $39.2B | $44.9B | $42.9B | $42.9B | $44.6B | ||
| Total Revenue | $18.3B | $20.9B | $24.4B | $25.5B | $32.2B | $39.2B | $44.9B | $42.9B | $42.9B | $44.6B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $8.2B | $9.0B | $9.7B | $10.0B | $16.2B | $19.6B | $25.9B | $25.8B | $25.2B | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $10.1B | $11.9B | $14.7B | $15.5B | $16.0B | $19.6B | $19.0B | $42.9B | $42.9B | $44.6B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $5.7B | $6.4B | $7.0B | $7.1B | $8.1B | $9.4B | $10.5B | $9.8B | $10.0B | $10.1B | ||
| Research & Development | $755.0M | $887.0M | $967.0M | $1.0B | $1.2B | $1.4B | $1.5B | $1.3B | $1.4B | $1.4B | ||
| Research Expense | $755.0M | $887.0M | $967.0M | $1.0B | $1.2B | $1.4B | $1.5B | $1.3B | $1.4B | $1.4B | ||
| Selling, General & Administrative | $5.0B | $5.5B | $6.1B | $6.1B | $6.9B | $8.0B | $9.0B | $8.4B | $8.6B | $8.7B | ||
| General & Administrative Expenses | $5.0B | $5.5B | $6.1B | $6.1B | $6.9B | $8.0B | $9.0B | $8.4B | $8.6B | $8.7B | ||
| Salaries & Wages | $133.0M | $159.0M | $181.0M | $181.0M | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $380.0M | $439.0M | $526.0M | $564.0M | $658.0M | $831.0M | $986.0M | $1.1B | $1.2B | -- | ||
| Depreciation & Amortization | $380.0M | $439.0M | $526.0M | $564.0M | $658.0M | $831.0M | -- | -- | -- | -- | ||
| Amortization | $21.3B | $25.3B | $25.3B | $-478.0M | $26.0B | $41.9B | $41.2B | $44.0B | $45.9B | -- | ||
| Other Operating Expenses | $-342.0M | $-565.0M | $-48.0M | $-53.0M | $-8.0M | $-32.0M | -- | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $2.4B | $3.0B | $3.8B | $4.6B | $7.8B | $10.0B | $8.4B | $6.9B | $7.3B | $7.7B | ||
| EBITDA | $3.8B | $4.5B | $5.5B | $6.2B | $10.1B | $12.0B | $11.8B | $11.0B | $11.5B | $11.5B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $469.0M | $592.0M | $667.0M | $676.0M | $553.0M | $536.0M | $726.0M | $1.4B | $1.4B | $1.4B | ||
| Intinc | $48.0M | $81.0M | $137.0M | $224.0M | $65.0M | $43.0M | $272.0M | $879.0M | $1.1B | $993.0M | ||
| Net Non-Operating Interest Income/Expense | $-421.0M | $-511.0M | $-530.0M | $-452.0M | $-488.0M | $-493.0M | $-454.0M | $-496.0M | $-312.0M | $-426.0M | ||
| Gain on Sale of Securities | $13.0M | $17.0M | $-15.0M | $44.0M | $10.0M | $66.0M | -- | -- | -- | -- | ||
| Other Income/Expense | $-20.8B | $-22.1B | $-9.0M | $72.0M | $79.0M | $698.0M | $-218.0M | $124.0M | $30.0M | $53.0M | ||
| Other Special Charges | $-9.0M | $-20.0M | $9.0M | $-72.0M | $-76.0M | $-694.0M | $-104.0M | $-65.0M | $12.0M | $-12.0M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-1.8B | $97.0M | $-14.0M | $52.0M | $51.0M | $37.0M | -- | -- | -- | -- | ||
| Special Income Charges | $1.8B | $-97.0M | $14.0M | $-52.0M | $-51.0M | $-37.0M | -- | $-194.0M | $-97.0M | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | $32.0M | $122.0M | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $2.0B | $2.5B | $3.2B | $4.0B | $7.8B | $9.4B | $8.4B | $7.6B | $8.4B | $8.7B | ||
| Pre-Tax Income | $2.0B | $2.4B | $3.3B | $4.1B | $7.2B | $8.8B | $7.8B | $6.3B | $7.0B | $7.3B | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-1.0M | $201.0M | $324.0M | $374.0M | $850.0M | $1.1B | $703.0M | $284.0M | $657.0M | $547.0M | ||
| NET INCOME | ||||||||||||
| Net Income | $2.0B | $2.2B | $2.9B | $3.7B | $6.4B | $7.7B | $7.0B | $6.0B | $6.3B | $6.7B | ||
| Net Income (Continuing Operations) | $2.0B | $2.2B | $2.9B | $3.7B | $6.4B | $7.7B | $7.0B | $6.0B | $6.3B | $6.7B | ||
| Net Income (Discontinued Operations) | $2.0B | $2.2B | $2.9B | $3.7B | $6.4B | $7.7B | $7.0B | $6.0B | $6.3B | $6.7B | ||
| Net Income (Common Stockholders) | $2.0B | $2.2B | $2.9B | $3.7B | $6.4B | $7.7B | $7.0B | $6.0B | $6.3B | $6.7B | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $7.2B | ||
| TOTALS | ||||||||||||
| Total Expenses | $13.9B | $15.4B | $16.7B | $17.2B | $19.5B | $23.0B | $36.4B | $9.8B | $10.0B | $10.1B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $394.8M | $395.0M | $402.0M | $400.0M | $396.0M | $394.0M | $392.0M | $386.0M | $382.0M | $377.0M | ||
| Average Shares Outstanding (Diluted) | $397.4M | $398.0M | $406.0M | $403.0M | $399.0M | $397.0M | $394.0M | $388.0M | $383.0M | $378.0M | ||
| Shares Outstanding | $390.4M | $401.8M | $399.0M | $398.8M | $393.8M | $391.2M | $385.4M | $381.3M | $377.3M | $371.6M | ||
| Basic EPS | $10.25 | $11.29 | $14.62 | $18.48 | $16.09 | $19.62 | $17.75 | $15.52 | $16.58 | $17.77 | ||
| Basic EPS (Continuing Operations) | $10.25 | $11.29 | $14.62 | $18.48 | $16.09 | $19.62 | $17.75 | $15.52 | $16.58 | $17.77 | ||
| Diluted EPS | $10.19 | $11.19 | $14.48 | $18.34 | $15.96 | $19.46 | $17.63 | $15.45 | $16.53 | $17.74 | ||
| Diluted EPS (Continuing Operations) | $10.19 | $11.19 | $14.48 | $18.34 | $15.96 | $19.46 | $17.63 | $15.45 | $16.53 | $17.74 | ||
| Dividend Per Share | $0.60 | $0.60 | $0.68 | $0.76 | $0.88 | $1.04 | $1.2 | $1.4 | $1.56 | $1.72 | ||
| OTHER METRICS | ||||||||||||
| Basic Discontinuous Operations | $-0.01 | $-0.01 | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Diluted Discontinuous Operations | $-0.01 | $-0.01 | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | -- | -- | $-3.0M | $-4.0M | $-172.0M | $-59.0M | $-42.0M | $-41.0M | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | $-3.0M | $-4.0M | $-172.0M | $-59.0M | $-42.0M | $-41.0M | ||
| Gain On Sale Of P P E | $-5.0M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | $482.0M | -- | -- | -- | -- | -- | -- | ||
| Interest Expense Operating | $-458.0M | $-533.0M | $-687.0M | $-790.0M | $-471.0M | $-555.0M | -- | -- | -- | -- | ||
| Minority Interests | -- | -- | -- | -- | $-2.0M | $-3.0M | $-10.0M | $40.0M | $-3.0M | $-17.0M | ||
| Net Income Discontinuous Operations | $-3.0M | $-3.0M | -- | $482.0M | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | $24.0M | $-27.0M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | $-3.0M | $-3.0M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $5.0B | $5.5B | $6.1B | $6.1B | $6.9B | $8.0B | $9.0B | $8.4B | $8.6B | $8.7B | ||
| Other Write Off | $9.0M | $10.0M | $12.0M | $32.0M | $34.0M | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $182.0M | $198.0M | $211.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | $-1.8B | $97.0M | $-14.0M | $52.0M | $51.0M | $37.0M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TMO | $448.18 | -0.0% | 1.94M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Thermo Fisher Scientific Inc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW